(Revival) Исследование по изучению эффективности и безопасности щелочной фосфатазы у пациентов с сепсис-ассоциированным ОПП
База данных, плацебо-контролируемое, две параллельные группы, РКИ фазы 3 для изучения эффективности и безопасности рекомбинантной щелочной фосфатазы человека для лечения пациентов с СА-ОПП
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis.
The study has three distinct SA-AKI trial populations:
- The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
- A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and <45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
- A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI.
In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients.
There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
Sepsis is the leading cause of acute kidney injury (AKI) and a major cause of death. Patients with SA-AKI have a high mortality and morbidity and are at risk of developing chronic kidney disease. AP is a homodimeric endogenous enzyme present in many cells and organs, e.g., intestines, placenta, liver, bone, kidney, and granulocytes. It exerts detoxifying effects through dephosphorylation of endotoxins; pathogen associated molecular pattern molecules (PAMPS e.g., lipopolysaccharide) and damage-associated molecular pattern molecules (DAMPS e.g., adenosine tri- and di-phosphate). In animal models of sepsis and AKI, administration of AP attenuates the inflammatory response, improves renal function and/or reduces mortality.
AM-Pharma B.V. is developing AP as a novel, recombinant chimeric human AP medicinal product, called recAP, to be used as an intravenous infusion for the treatment of SA-AKI. In the Phase 2 trial STOP-AKI, a survival benefit was observed in the two highest dose groups, 0.8 mg/kg and 1.6 mg/kg groups, compared to the placebo group. There were no safety or tolerability concerns for any of the doses tested (0.4, 0.8 and 1.6 mg/kg). The 1.6 mg/kg recAP dose was selected for this Phase 3 trial based on the significant survival benefit observed. PK/PD simulations also confirmed this dose to have the most pronounced treatment effect.
The primary objective of this Phase 3 trial is to confirm the mortality benefit seen in STOP-AKI by demonstrating a reduction in 28 day all cause mortality in patients with SA-AKI treated with 1.6 mg/kg recAP.
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Bedford Park, Австралия, 5042
- Flinders Medical Centre
-
Bendigo, Австралия, 3550
- Bendigo Hospital
-
Footscray, Австралия, 3011
- Footscray Hospital
-
Melbourne, Австралия, 3084
- Austin Hospital
-
New Lambton Heights, Австралия, 2305
- John Hunter Hospital
-
Saint Albans, Австралия, 3021
- Sunshine Hospital ICU - Western Hospital
-
Southport, Австралия, 4215
- Gold Coast University Hospital (GCUH)
-
-
-
-
-
Graz, Австрия, 8036
- Medizinische Universitaet Graz - Klinik fuer Innere Medizin
-
Innsbruck, Австрия, 6020
- Medizinische Universität Innsbruck
-
Innsbruck, Австрия, 6020
- Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Innere Medizin I
-
-
-
-
-
Brussels, Бельгия, 1020
- Centre Hospitalier Universitaire Brugmann
-
Charleroi, Бельгия, 6042
- Centre Hospitalier Universitaire (CHU) de Charleroi - Hopital Civil Marie Curie
-
Genk, Бельгия, 3600
- Ziekenhuis Oost-Limburg
-
Ghent, Бельгия, 9000
- Universitair Ziekenhuis Gent
-
Jette, Бельгия, 1090
- Universitair Ziekenhuis Brussel
-
La Louvière, Бельгия, 7100
- Hôpital de JOLIMONT
-
Ottignies, Бельгия, 1340
- Clinique Saint-Pierre- Ottignies
-
Woluwe-Saint-Lambert, Бельгия, 1200
- Cliniques Universitaires Saint-Luc
-
Yvoir, Бельгия, 5530
- CHU UCL Namur - Mont-Godinne
-
-
-
-
-
Aachen, Германия, 52074
- Universitätsklinikum Aachen
-
Hamburg, Германия, 20246
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Jena, Германия, 7747
- University Hospital Jena - Klinik fur Neurologie
-
Leipzig, Германия, 4103
- Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Gastroenterologie und Rheumatologie
-
Münster, Германия, 48149
- University Hospital Münster
-
-
-
-
-
Aalborg, Дания, 9000
- Aalborg Universitetshospital
-
Aarhus N, Дания, 8200
- Aarhus University Hospital
-
Copenhagen, Дания, 2100
- Rigshospitalet
-
Herning, Дания, 7400
- Herning Regional Hospital
-
Hillerød, Дания, 3400
- Nordsjællands Hospital
-
Køge, Дания, 4600
- Sjaellands Universitetshospital, Koge - Kardiologisk Afdeling
-
Odense C, Дания, 5000
- Odense Universitetshospital
-
Randers, Дания, 8930
- Regionshospitalet Randers
-
Slagelse, Дания, 4200
- Slagelse Sygehus
-
Viborg, Дания, 8800
- Hospitalsenhed Midt
-
-
-
-
-
Dublin, Ирландия, D08 NHY1
- St. James's Hospital
-
Dublin, Ирландия, D24NR0A
- Tallaght University Hospital
-
Dublin, Ирландия, Dublin 4
- St. Vincent's University Hospital
-
-
G
-
Galway, G, Ирландия, H91 YR71
- National University of Ireland, Galway
-
-
-
-
-
Badalona, Испания, 8916
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, Испания, 8035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Испания, 8907
- Hospital Universitari de Bellvitge (IDIBELL)
-
Barcelona, Испания, 8003
- Hospital del Mar
-
Girona, Испания, 17007
- Hospital Universitari de Girona Doctor Josep Trueta
-
Madrid, Испания, 28040
- Hospital Clínico San Carlos
-
Sabadell, Испания, 8208
- Parc Taulí Sabadell Hospital Universitari
-
Terrassa, Испания, 8221
- Universitat de Barcelona - Hospital Universitari Mutua Terrassa (HUMT)
-
-
-
-
-
Calgary, Канада, T1Y 6J4
- Peter Lougheed Centre
-
Calgary, Канада, T2N 2T9
- Foothills Medical Centre
-
Calgary, Канада, T2V 1P9
- Rockyview General Hospital
-
Calgary, Канада, T3M 1M4
- Alberta Health Services - South Health Campus Hospital
-
Ottawa, Канада, K1H 8L6
- The Ottawa Hospital - General Campus
-
Ottawa, Канада, K1Y 4E9
- The Ottawa Hospital - Civic Campus
-
Québec, Канада, G1J 1Z4
- Hôpital de l'Enfant-Jésus
-
Vancouver, Канада, V6Z 1Y6
- St. Paul's Hospital
-
Victoria, Канада, V8R 1J8
- Royal Jubilee Hospital (RJH)
-
Victoria, Канада, V8R 1J8
- Victoria General Hospital (VGH)
-
-
-
-
-
Amsterdam, Нидерланды, 1081 HV
- Amsterdam UMC - VUMC
-
Ede, Нидерланды, 6716 RP
- Ziekenhuis Gelderse Vallei
-
Enschede, Нидерланды, KZ 7512
- Medisch Spectrum Twente
-
Heerlen, Нидерланды, Heerlen
- Zuyderland Medisch Centrum, Heerlen
-
Nijmegen, Нидерланды, 6532 SZ
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen, Нидерланды, 6500 HB
- Radboud UMC
-
-
North Brabant
-
's-Hertogenbosch, North Brabant, Нидерланды, 5223 GZ
- Jeroen Bosch Ziekenhuis lokatie GZG
-
-
-
-
-
Auckland, Новая Зеландия, 1023
- Auckland City Hospital
-
Auckland, Новая Зеландия, 2025
- Middlemore Clinical Trials
-
Christchurch, Новая Зеландия, 8140
- Christchurch Hospital
-
Dunedin, Новая Зеландия, 9016
- Dunedin Hospital
-
Grafton, Новая Зеландия, 1023
- Auckland City Hospital
-
Hastings, Новая Зеландия, 4172
- Hawke's Bay Hospital Soldiers' Memorial
-
Rotorua, Новая Зеландия, 3046
- Lakes District Health Board - Rotorua Hospital
-
-
WGN
-
Wellington, WGN, Новая Зеландия, 6021
- Wellington Hospital
-
-
-
-
-
Cardiff, Соединенное Королевство, CF14 4XW
- University Hospital of Wales
-
Liverpool, Соединенное Королевство, L7 8XP
- Royal Liverpool University Hospital
-
London, Соединенное Королевство, SE1 7EH
- Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
-
Plymouth, Соединенное Королевство, PL6 8DH
- Plymouth Hospitals NHS Trust - Derriford Hospital
-
-
LND
-
London, LND, Соединенное Королевство, NW1 2BU
- University College London Hospitals NHS Foundation Trust - University College Hospital
-
-
-
-
Arizona
-
Tucson, Arizona, Соединенные Штаты, 85724-5057
- The University of Arizona Cancer Center
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90095-8358
- Ronald Reagan UCLA Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20037-2342
- The George Washington University Medical Faculty Associates - Anesthesiology
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322-1007
- Emory Clinical Cardiovascular Research Institute
-
-
Illinois
-
Glenview, Illinois, Соединенные Штаты, 60026-1301
- Glenbrook Hospital
-
Highland Park, Illinois, Соединенные Штаты, 60035
- NorthShore Medical Group - Bannockburn
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40508-3215
- University of Kentucky College of Medicine (UKCM)
-
-
Minnesota
-
Saint Paul, Minnesota, Соединенные Штаты, 55101
- Regions Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Соединенные Штаты, 87131
- University of New Mexico School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Wake Forest Baptist Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, Соединенные Штаты, 43210
- The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213-3108
- UPMC CancerCenter at Magee - Womens Hospital
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213-3108
- UPMC Presbyterian
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908-0817
- University of Virginia Health System
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226-3522
- Froedtert & the Medical College of Wisconsin Froedtert Hospital
-
-
-
-
-
Helsinki, Финляндия, 290
- Helsinki University Central Hospital (HUCH)
-
Tampere, Финляндия, 33521
- Tampere University Hospital
-
Turku, Финляндия, 20521
- Turku University Hospital (TYKS)
-
-
-
-
-
Angers, Франция, 49933
- Centre Hospitalier Universitaire d'Angers
-
Argenteuil, Франция, 95107
- Centre Hospitalier d'Argenteuil
-
Béthune, Франция, 62408
- Centre Hospitalier de Bethune Germon et Gauthier
-
Cergy-Pontoise, Франция, 95303
- Centre Hospitalier René-Dubos
-
Dijon, Франция, 21079
- CHU Dijon - Hôpital François Mitterrand
-
La Roche-sur-Yon, Франция, 85000
- Centre Hospitalier Départemental de Vendée - Les Oudairies
-
Le Kremlin-Bicêtre, Франция, 94270
- Hôpital Bicêtre
-
Le Mans, Франция, 72000
- Centre Hospitalier du Mans
-
Limoges, Франция, 87000
- CHU Limoges - Hôpital Dupuytren
-
Nancy, Франция, 54000
- CHU de Nancy
-
Nantes, Франция, 44000
- CHU de Nantes - Hôtel-Dieu
-
Nîmes, Франция, 30029
- CHU de Nimes - Hopital Universitaire Caremeau
-
Orléans, Франция, 45067
- Hôpital La Source
-
Paris, Франция, 75010
- Hôpital Lariboisière
-
Strasbourg, Франция, 67091
- Hôpitaux Universitaires de Strasbourg - Hôpital Civil
-
Tours, Франция, 37044
- CHRU de Tours - Hôpital Bretonneau
-
-
-
-
-
Hachioji-Shi, Япония, 193-0998
- Tokyo Medical University Hachioji Medical Center
-
Hiroshima, Япония
- Hiroshima University Hospital
-
Izuka-shi, Япония, 820-8505
- Aso Iizuka Hospital
-
Izumisano, Япония, 598-8577
- Rinku General Medical Center
-
Kashihara-shi, Япония, 634-8522
- Nara Medical University Hospital
-
Kumamoto, Япония, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
Osaka, Япония, 534-0021
- Osaka City General Hospital
-
Osaka, Япония, 543-0035
- Osaka Police Hospital
-
Toyoake-Shi, Япония, 470-1192
- Fujita Health University Hospital
-
Yokohama, Япония, 245-8575
- National Hospital Organization - Yokohama Medical Center
-
Ōmihachiman, Япония, 523-0082
- Omihachiman Community Medical Center
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
18 years or older.
-
In the ICU or intermediate care unit for clinical reasons.
-
Have sepsis requiring vasopressor (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, or angiotensin II) therapy, i.e.:
- suspected or proven bacterial or viral infection. and
- on vasopressor therapy (≥0.1 µg/kg/min norepinephrine or equivalent) for sepsis-induced hypotension for at least one hour despite adequate fluid resuscitation according to clinical judgement. Following the initial one hour on at least 0.1 µg/kg/min norepinephrine or equivalent, any dose of vasopressor counts as vasopressor therapy.
The combination of a) and b) automatically ensures that patients fulfill the Sepsis 3 criteria as 0.1 µg/kg/min norepinephrine corresponds to a score of +4 on the Cardiovascular sub-score of the SOFA score.
-
Have AKI according to at least one of the below KDIGO criteria, a to d:
-
An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours.
or
-
A relative increase in CR to ≥1.5 times the pre-AKI reference CR value which is known or presumed to have occurred within prior 7 days.
or
-
A decrease in urinary output to <0.5 mL/kg/hour for a minimum of 6 hours following adequate fluid resuscitation.
or d) If the patient does not have a known history of CKD and there is no pre-AKI reference CR value available from the past 12 months available from the past 12 months: a CR value greater or equal to the levels presented in Table 1, with the increase in CR presumed to have occurred within prior 7 days.
-
-
Provision of signed and dated ICF in accordance with local regulations.
Exclusion Criteria:
-
a) At sites where enrolment of 'moderate' CKD patients is allowed, patients with 'severe' CKD defined as a pre-AKI reference eGFR <25 mL/min/1.73 m2 are excluded.
-
For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥25 mL/min/1.73 m2.
-
For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 25-60 mL/min/1.73 m2 can also be used to rule out 'severe' CKD.
b) At sites where enrolment of 'moderate' CKD patients is NOT allowed, patients with 'moderate' and 'severe' CKD defined as a pre-AKI reference eGFR <45 mL/min/1.73 m2 are excluded.
-
For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥45 mL/min/1.73 m2.
-
For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 45-60 mL/min/1.73 m2 can also be used to rule out 'moderate' and 'severe' CKD.
-
-
Advanced chronic liver disease, defined as a Child-Pugh score of 10 to 15 (Class C).
-
Acute pancreatitis without proven infection.
-
Urosepsis related to suspected or proven urinary tract obstruction.
-
Main cause of AKI not sepsis.
-
Proven or suspected SARS-CoV-2 infection. NOTE: This exclusion criterion does not apply to patients in the COVID-19 population, in which COVID-19 should be the main cause of SA-AKI.
-
Severe burns requiring ICU treatment.
-
Severely immunosuppressed, e.g. due to:
- hematopoietic cell transplantation within past 6 months prior to Screening or acute or chronic graft-versus-host disease
- solid organ transplantation
- leukopenia not related to sepsis, i.e., preceding sepsis
- Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
- receiving chemotherapy within 30 days prior to Screening.
-
At high risk of being LTFU, e.g., due to known current or recent (within the last 6 months) IV drug abuse or known to be homeless.
-
Limitations to use of mechanical ventilation (MV), RRT or vasopressors and inotropes (NOTE: limitation of cardiopulmonary resuscitation (CPR) only is not an exclusion criterion).
-
Previous administration of recAP.
-
Use of a non-marketed drug within the last month or concurrent or planned participation in a clinical trial for a non-marketed drug or device. (NOTE: Co-enrollment or concurrent participation in observational, non-interventional trials using no protocolized treatments or procedures are always allowed. Co-enrollment or concurrent participation in trials using protocolized treatments or procedures, e.g. blood draws, requires pre-approval by the TSC).
-
Current or planned extracorporeal membrane oxygenation (ECMO).
-
On RRT >24 hours before start of trial drug.
-
No longer on vasopressor therapy at time of randomization.
-
On continuous vasopressor therapy for >72 hours before start of trial drug.
-
Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 based on the most recent available CR sample at time of screening (NOTE: will often be the sample used to diagnose AKI). eGFR should be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In Japan, the CKD-EPI formula with Japanese coefficient should be used. If local regulations prohibit correcting for race in the calculation of eGFR, it is acceptable to use the formula without correcting for race.
-
Not feasible to start trial drug within:
-
48 hours from AKI diagnosis, when AKI diagnosis precedes start of vasopressor therapy.
or
-
24 hours from AKI diagnosis, when AKI is diagnosed after start of vasopressor therapy.
-
-
Pregnant or nursing women.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Плацебо Компаратор: placebo
matching placebo |
Placebo |
|
Экспериментальный: active
recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions |
patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
28-day All-cause Mortality: Main Trial Population
Временное ограничение: 28 days
|
To demonstrate an effect of recAP on 28 day all cause mortality |
28 days
|
|
28-day All-cause Mortality: Moderate Chronic Kidney Disease Population
Временное ограничение: 28 days
|
To demonstrate an effect of recAP on 28 day all cause mortality |
28 days
|
|
28-day All-cause Mortality: COVID-19 Population
Временное ограничение: 28 days
|
To demonstrate an effect of recAP on 28 day all cause mortality |
28 days
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Major Adverse Kidney Events 90: Main Trial Population
Временное ограничение: 90 Days
|
Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
90 Days
|
|
Major Adverse Kidney Events 90: Moderate Chronic Kidney Disease Population
Временное ограничение: 90 Days
|
Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
90 Days
|
|
Major Adverse Kidney Events 90: COVID-19 Population
Временное ограничение: 90 Days
|
Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
90 Days
|
|
Major Adverse Kidney Events Through Day 90: Combined Population
Временное ограничение: 90 Days
|
Major Adverse Kidney Events through day 90 (MAKE90A) :
|
90 Days
|
|
Days Alive and Free of Organ Support Through Day 28: Main Trial Population
Временное ограничение: 28 days
|
Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
28 days
|
|
Days Alive and Free of Organ Support Through Day 28: Moderate Chronic Kidney Disease Population
Временное ограничение: 28 days
|
Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
28 days
|
|
Days Alive and Free of Organ Support Through Day 28: COVID-19 Population
Временное ограничение: 28 days
|
Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
28 days
|
|
Days Alive and Out of the ICU Through Day 28: Main Trial Population
Временное ограничение: 28 days
|
Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
28 days
|
|
Days Alive and Out of the ICU Through Day 28: Moderate Chronic Kidney Disease Population
Временное ограничение: 28 days
|
Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
28 days
|
|
Days Alive and Out of the ICU Through Day 28: COVID-19 Population
Временное ограничение: 28 days
|
Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
28 days
|
|
90-day All Cause Mortality: Main Trial Population
Временное ограничение: 90 days
|
90-Day all-cause mortality |
90 days
|
|
90-day All Cause Mortality: Moderate Chronic Kidney Disease Population
Временное ограничение: 90 days
|
90-Day all-cause mortality |
90 days
|
|
90-day All Cause Mortality: COVID-19 Population
Временное ограничение: 90 days
|
90-Day all-cause mortality |
90 days
|
Соавторы и исследователи
Спонсор
Спонсор
Следователи
Следователи
- Директор по исследованиям: A Legters, AM-Pharma
Публикации и полезные ссылки
Общие публикации
- Pickkers P, Angus DC, Arend J, Bellomo R, van den Berg E, Bernholz J, Bestle M, Broglio K, Carlsen J, Doig CJ, Ferrer R, Joannidis M, Francois B, Doi K, Kellum JA, Laterre PF, Liu K, Mehta RL, Murray PT, Ostermann M, Pettila V, Richards S, Young P, Zarbock A, Kjolbye AL. Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury. BMJ Open. 2023 Apr 3;13(4):e065613. doi: 10.1136/bmjopen-2022-065613.
- Pickkers P, Angus DC, Bass K, Bellomo R, van den Berg E, Bernholz J, Bestle MH, Doi K, Doig CJ, Ferrer R, Francois B, Gammelager H, Pedersen UG, Hoste E, Iversen S, Joannidis M, Kellum JA, Liu K, Meersch M, Mehta R, Millington S, Murray PT, Nichol A, Ostermann M, Pettila V, Solling C, Winkel M, Young PJ, Zarbock A; REVIVAL investigators. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL). Intensive Care Med. 2024 Jan;50(1):68-78. doi: 10.1007/s00134-023-07271-w. Epub 2024 Jan 3.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Действительный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- AP-recAP-AKI-03-01
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .